Tocilizumab for the treatment of severe coronavirus disease 2019

Tocilizumab, an interleukin‐6 inhibitor, may ameliorate the inflammatory manifestations associated with severe coronavirus disease 2019 (COVID‐19) and thus improve clinical outcomes. This was a retrospective review of patients with laboratory‐confirmed severe COVID‐19 who received tocilizumab and co...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Med Virol
Päätekijät: Alattar, Rand, Ibrahim, Tawheeda B. H., Shaar, Shahd H., Abdalla, Shiema, Shukri, Kinda, Daghfal, Joanne N., Khatib, Mohamed Y., Aboukamar, Mohamed, Abukhattab, Mohamed, Alsoub, Hussam A., Almaslamani, Muna A., Omrani, Ali S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2020
Aiheet:
Research Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7267594/
https://ncbi.nlm.nih.gov/pubmed/32369191
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jmv.25964
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia